EcoDrugPlus

Protein Kinase Camp-Activated Catalytic Subunit Beta

Ensembl ID : ENSDNOG00000017990
Gene Symbol: PRKACB
2 Cross references
304 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSDNOG00000014147
Gene Symbol: PRKDC
4 Cross references
187 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSDNOG00000030654
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSDNOG00000017110
Gene Symbol: PTK2
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSDNOG00000007032
Gene Symbol: PTK2B
4 Cross references
213 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSDNOG00000036677
Gene Symbol: PTPN11
4 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSDNOG00000019239
Gene Symbol: PTPRB
2 Cross references
268 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSDNOG00000044964
Gene Symbol: PNP
3 Cross references
87 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSDNOG00000003606
Gene Symbol: P2RX3
2 Cross references
272 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSDNOG00000014586
Gene Symbol: P2RX7
4 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSDNOG00000034630
Gene Symbol: P2RY1
4 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSDNOG00000010893
Gene Symbol: P2RY12
4 Cross references
182 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).